[Short-lasting infusions of Fibraccel following aortocoronary bypass surgery. The effect on postoperative blood loss and hemostasis depending on the time of extracorporeal circulation].
Bleeding is a major problem in the post-operative period (p.o.) after aortocoronary bypass surgery. Harke et al. have investigated the beneficial effect of homologous phospholipid complex (Fibraccel) after mitral and/or aortic valve replacement. No actual data were available evaluating therapy with Fibraccel after aortocoronary bypass grafting. We were especially interested in the influence of Fibraccel on routine blood coagulation parameters: partial thromboplastin time (PTT), thrombin time (TT), prothrombin time = Quick fibrinogen, platelet count and activated clotting time, spontaneous platelet aggregation (alpha 2/Tr, platelet aggregation test II of Breddin), thrombelastography, blood loss from the chest drain, use of fresh frozen plasma, and side-effects of the substance after aortocoronary bypass grafting. Forty patients (6 female, 35 male, mean age 58 years, ASA III-IV) were studied in a randomized order. Patients who had acetylsalicylic acid (ASS) or anticoagulants during the last 7 days before operation were excluded. In 20 patients 50-ml Fibraccel infusions lasting 30 min each were started immediately after antagonism by protamine chloride. Subsequent 50-ml Fibraccel infusions were given every 4 h until 20 h after extracorporeal circulation (ECC). The other 20 patients received placebo infusions at corresponding times. Each patient had a routine ASS medication (0.5 gi.v) about 8 h p.o. Blood samples for immediate analysis were taken: I = before operation; II = after ECC, before protamine; III = 90 min after protamine; IV = on the first p.o. day (20.5 h after protamine).(ABSTRACT TRUNCATED AT 250 WORDS)
Duda
D
D
Klinik für Anaesthesiologie, Johannes Gutenberg-Universität Mainz.
Brandt
L
L
Ohler
W
W
D001777:Blood Coagulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D005112:Extracorporeal Circulation; D005260:Female; D006488:Hemostasis, Surgical; D006490:Hemostatics / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009930:Organic Chemicals; D011897:Random Allocation; D013997:Time Factors
D006490:Hemostatics; D009930:Organic Chemicals; C049026:fibraccel
Fibraccel-Kurzinfusionen nach aorto-koronaren Bypass-Operationen. ECC-Zeit-abhängiger Einfluss auf den postoperativen Blutverlust und die Hämostase.